Publication date: Sep 04, 2025
Deep mutational scanning (DMS), a high-throughput method leveraging next-generation sequencing, has been crucial in mapping the functional landscapes of key severe acquired respiratory syndrome-coronavirus 2 (SARS-CoV-2) proteins. By systematically assessing thousands of amino acid changes, DMS provides a framework to understand Angiotensin-converting enzyme 2 (ACE2) binding and immune evasion by the spike protein, mechanisms and drug escape potential of the main and papain-like viral proteases and has highlighted areas of concern in the nucleocapsid protein that may affect most currently available rapid antigen testing kits. Each application has required the design of bespoke assays in eukaryotic (yeast and mammalian) cell models, providing an exemplar for the application of this technique to future pandemics. This minireview examines how DMS has predicted key evolutionary changes in SARS-CoV-2 and affected our understanding of SARS-CoV-2 biology, specifically highlighting their relevance for therapeutics development.
| Concepts | Keywords |
|---|---|
| Biochem | deep mutational scanning |
| Coronavirus | nucleocapsid |
| Pandemics | SARS-CoV-2 |
| Thousands | spike |
| Yeast | viral proteases |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | emerging pathogen |
| drug | DRUGBANK | Succimer |
| disease | MESH | syndrome |
| disease | IDO | protein |
| drug | DRUGBANK | Papain |
| disease | IDO | cell |